Timeline of How GLP-1s Work: Week 1-2: Medication reaches therapeutic levels Begin noticing reduced appetite Food sounds less appealing Easier to stop eating when satisfied Week 3-4: Appetite suppression more pronounced Portions naturally smaller Less frequent eating First measurable weight loss (3-5 pounds) Week 5-12: Steady appetite control Consistent portion reduction Weight loss accelerates (1-2 pounds weekly) Side effects typically improving Month 4-6: Dose increases continue (if tolerating well) Sustained weight loss (10-15 pounds total) New eating habits feeling normal Significant results becoming visible Month 7-12: Approaching or reaching maintenance dose Steady continued weight loss Total loss: 15-30 pounds depending on starting weight Metabolic improvements evident in lab work Month 13-20: Maximum weight loss achieved Average 10-22% total body weight lost Maintenance phase begins Focus shifts to sustaining results What GLP-1s DONT Do: Common Misconceptions: They dont: Burn fat directly like thermogenic supplements Block calorie absorption like fat blockers Speed up metabolism dramatically Work without you eating less (you eat less naturally) Cure obesity (stopping leads to weight regain) Eliminate need for healthy habits They do: Make eating less feel natural and sustainable Reduce biological hunger signals Help you consume fewer calories without constant struggle Provide biological support for behavioral changes Treat obesity as the chronic condition it is Why GLP-1s Succeed Where Other Approaches Fail: The Biological Barrier: When you lose weight through calorie restriction alone: Your body produces more hunger hormone (ghrelin) Satiety hormones (leptin, GLP-1) decrease Metabolism slows by 15-20% Cravings intensify Your body fights to regain weight This is why 80-95% of people who lose weight through diet alone regain it
Scroll to continue reading For many Black households, access to preventive care, healthy food, safe environments for exercise, and consistent insurance coverage is already fragile
Coskuns research contributions span the entire development arc of GLP3 : Discovery and initial characterization of GLP3 s triple-receptor agonist properties and pharmacological profile Preclinical studies establishing proof-of-mechanism in mouse models and in vitro receptor systems Design and medical oversight of phase 1b and phase 2 clinical trials in type 2 diabetes and obesity Investigation of GLP3 s effects on gastric emptying and mechanistic studies of weight loss Contribution to over 168 peer-reviewed publications in metabolic disease research with citation impact exceeding 8,700 citations His work extends beyond GLP3 to include fundamental contributions to the development of GLP2 and advancement of incretin-based therapeutics more broadly
Our team will share information about different peptide categories, current scientific studies, and safe research practices
that causes shrinking of the guard cells which results in stomatal closure (Mittler and Blumwald 2015)
